行情

CFRX

CFRX

ContraFect
NASDAQ

实时行情|Nasdaq Last Sale

1.135
+0.015
+1.34%
盘后: 1.150 +0.015 +1.32% 16:54 01/22 EST
开盘
1.140
昨收
1.120
最高
1.150
最低
1.060
成交量
299.88万
成交额
--
52周最高
1.340
52周最低
0.2693
市值
1.74亿
市盈率(TTM)
25.80
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CFRX 新闻

  • 美油周三收跌2.8% 创12月初以来新低
  • 新浪美股.57分钟前
  • 黄金期货周三收跌约0.1% 白银收高0.1%
  • 新浪美股.1小时前
  • 尾盘:标普与纳指创盘中新高 英特尔与IBM领涨
  • 新浪美股.1小时前
  • 亿万富豪马克库班:仍看多Netflix 一股也没卖
  • 新浪美股.3小时前

更多

所属板块

生物技术和医学研究
+0.09%
制药与医学研究
-0.21%

热门股票

名称
价格
涨跌幅

CFRX 简况

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.
展开

Webull提供ContraFect Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。